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In the present study we demonstrate that azathioprine (AZA) inhibits vaccinia virus (VV) replication in both BSC-40 and RAG
cell lines, acting on different stages of virus cycle. In BSC-40 cells, early protein synthesis was not significantly affected, but
late gene expression was severely impaired. In RAG cells all stages of gene expression were completed during synchronous
infection in the presence of the drug. The onset of DNA replication was not affected in RAG cells, but a severe inhibition was
observed in BSC-40 cells. Electron microscopic analysis of VV-infected RAG cells treated with AZA revealed brick-shaped
particles presenting abnormal definition of the internal structure. Purified virions from AZA-treated RAG cells presented
several modifications of the protein content, a lesser amount of DNA, and a lower PFU:particle ratio. Our results suggest thatINTRODUCTION
Vaccinia virus (VV), the prototype member of the Pox-
viridae family, replicates exclusively within the cytoplasm
of infected cells in a near-independence of host-cell
functions (Moss, 2001). VV contains a large double-
strand DNA genome, which encodes many enzymes
required for viral replicative cycle. The partial autonomy
and a temporarily well-defined infectious cycle have
made VV an excellent model of study for gene expres-
sion and virus–host interactions. Early viral gene expres-
sion is mediated by the transcription machinery pack-
aged within the infecting virions. This step ceases with
the disassembly of the particle and the release of the
genome viral DNA, which is then replicated by enzymes
encoded by early viral genes. After the onset of viral DNA
replication, intermediate and late transcription occurs in
a cascade way where each phase of macromolecule
synthesis depends on the proper execution of the previ-
ous stage. Concurrent with late gene expression, the
assembly of new viral particles initiates asynchronously
and proceeds continuously during the late stage of virus
replicative cycle. The final steps of virus morphogenesis
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microscopy (Rodriguez et al., 1997; Sodeik et al., 1993,
1994).
Azathioprine (AZA) [6-(1-methyl-4-nitro-5-imidazolyl)
thiopurine] is both an immunosuppressive and an anti-
leukemic drug that has been extensively used in clinic
(Aarbakke et al., 1997; Elion, 1977, 1989). As an inactive
prodrug, AZA only exerts cytotoxicity after its metabolism
to thiopurine nucleotide derivatives. AZA is a substrate
for cellular enzymes involved in purine nucleotide bio-
synthesis, such as hypoxanthine-guanine-phosphoribo-
syltransferase (HGPRT) (De Miranda et al., 1975; Elion,
1993). Effectiveness of AZA therapy has been related to
the incorporation of the thionucleotides, produced
through AZA catalysis, into DNA molecules (Swann et al.,
1996). Thus, the mechanism of action of AZA probably
resides on its inhibitory effects on the salvage pathway
of purine nucleotide biosynthesis. Cell lines mutant in
the HGPRT gene, such as RAG, are resistant to several
purine analogs (O’Brien, 1976).
Data from the literature showed that some immuno-
modulators, such cyclosporin A, FK-506, and lefluno-
mide, exert inhibitory effects against viral targets in cell
culture (Damaso and Keller, 1994; Karpas et al., 1992;
Knight et al., 2001). In the case of AZA, an antiviral activity
was previously reported using immunosuppressive
doses against human cytomegalovirus (HCMV) and
doses several times greater against herpes simplex vi-
rus (HSV) and varicella-zoster virus (VZV) (Shiraki et al.,
1991). Although virus replication could be inhibited byin VV-infected RAG cells AZA interfered with virus morphoge
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Universidade Federal do Rio de Janeiro, Ilha do Funda˜o, 21941-590, Rio
de Janeiro, Brazil. Fax: 55 (21) 2280-8193. E-mail: nissin@biof.ufrj.br.
doi:10.1006/viro.2002.1534whereas in BSC-40 cells the replicative cycle was inhibited
AZA, its mechanism of action is unknown and the step of
the replicative cycle affected was not determined.
0042-6822/02 $35.00nesis,© 2002 Elsevier Science (USA)
All rights reserved.
In this article we show that AZA exerts an antiviral
activity on VV replication. We analyzed AZA antiviral po-
tential in two different cell systems, BSC-40 cells and
RAG cells, which is HGPRT-deficient. Although virus yield
is inhibited in both BSC-40 and RAG cell lines treated
with AZA, virus macromolecular synthesis is affected
only in VV-infected BSC-40 cells. In RAG cells infected
with VV, virus morphogenesis seems to be the target
step to AZA treatment, with little effect on viral gene
expression.
RESULTS
Azathioprine inhibits vaccinia replication in cultured
cell lines
It was reported that thiopurine nucleotides formed due
to AZA metabolism can inhibit nucleic acid synthesis by
incorporation of thioguanine nucleotides into DNA and
RNA, also exerting antiproliferative effects (Aarbakke et
al., 1997). Hypoxanthine-guanine-phosphoribosyltrans-
ferase is an enzyme primarily involved in the conversion
of AZA products into thioguanine nucleotides, and cell
lines deficient in HGPRT activity are resistant to several
purine analogs (Elion, 1993). Therefore, it was in our
interest to perform a comparative study on the effects of
AZA on VV replication in BSC-40 and RAG cells; the last
one is deficient in HGPRT (O’Brien, 1976).
Preliminary observation from our group showed that
AZA reduced VV plaque number and size when added to
BSC-40 monolayers for 48 h (data not shown). To study
the effect of AZA on VV infectious cycle, the production of
virus particles was first examined under different con-
centrations of AZA. BSC-40 and RAG cells were infected
with VV at an m.o.i. of 10, and after adsorption the
monolayers were overlaid with medium containing AZA
in the range of 0–40 g/ml, as described. After 24 h of
infection, the cells were harvested for yield titration by
plaque assay. Figure 1 shows that AZA inhibited VV
replication in BSC-40 cells in a dose-dependent manner.
Unexpectedly, virus replication in RAG monolayers was
also severely affected by AZA treatment. The IC50 values
of AZA were very similar, with 6.3 and 7.24 g/ml in
BSC-40 and RAG cells, respectively. For the next set of
experiments we then chose to work with 25 g/ml AZA
that led to an inhibition of virus yield of 95 and 97% in
BSC-40 and RAG cells, respectively, and with minimal
cytotoxic effect to the host cells. Toxicity of AZA to unin-
fected monolayers was determined by inhibition of cell
growth and by trypan blue exclusion. In Table 1 we show
that in BSC-40 cells AZA exerted cytotoxic effect only
after 48 h of treatment at 40 g/ml, but no cytotoxic effect
was observed in RAG cells in the same assay conditions.
The effect of AZA was also analyzed on the production
of infectious particles during a one-step growth experi-
ment in BSC-40 and RAG cells. In both cell lines, the
accumulation of infective progeny started to increase at
9 h postinfection and progressed during infection up to
24 h in the absence of AZA (Fig. 2). The addition of 25
g/ml AZA after adsorption decreased the rate of VV
yield significantly after 9 h postinfection in BSC-40 (Fig.
2A) and RAG cells (Fig. 2B). The inhibition in virus titer at
FIG. 1. Dose-dependent inhibition of vaccinia virus production by
AZA. BSC-40 and RAG cells were infected with VV at a multiplicity of 10.
At zero time, AZA at different concentrations was added to the culture
media. After 24 h of infection the monolayers were collected for virus
titration by plaque assay. 100% refers to the virus yield produced in
cells infected in the presence of 0.1% DMSO (F) BSC-40  7.9  107
PFU/ml; () RAG  6.6  108 PFU/ml.
TABLE 1
Cell Growth and Cytotoxicity during AZA Treatment
Cell line AZA (g/ml)
24 ha 48 ha
No. cells  104 % Control % Dead cells No. cells  104 % Control % Dead cells
BSC-40 0 82.3 100.0 2.27 135.5 100.0 2.58
25 80.5 97.8 3.10 113.8 84.0 8.00
40 73.3 89.0 5.65 93.4 68.9 20.70
RAG 0 98.5 100.0 3.42 152.6 100.0 3.85
25 99.1 100.6 3.15 152.1 99.6 3.80
40 98.1 99.6 3.31 153.8 100.7 3.82
a Indicates the time in hours that the cells were incubated with AZA.
80 DAMASO ET AL.
24 h postinfection occurred at levels similar to those
obtained in Fig. 1.
Analysis of viral DNA accumulation in AZA-treated cells
Although AZA inhibited the production of VV progeny
in BSC-40 and RAG cells, the experiments did not dis-
cern which stage of virus cycle was affected by the drug.
Since AZA is reported to affect the purine nucleotide
biosynthesis and, consequently, the DNA metabolism,
we examined virus DNA replication throughout infection
in the presence of AZA. Extracts of infected cells were
applied on a membrane of a slot-blot apparatus and
hybridized to 32P-labeled fragments of the viral genome
(Damaso and Keller, 1994). Scanning of the slot-blot
autoradiogram revealed that viral DNA was initially de-
tected at 2 to 3 h postinfection and accumulated as
infection proceeded in untreated BSC-40 and RAG cells
(Fig. 3). However, in BSC-40 monolayers treated with
AZA, the onset of virus DNA synthesis was delayed, and
the rate of DNA accumulation was drastically slowed
between 4 and 12 h postinfection. The level of accumu-
lation at 12 h postinfection was reduced in almost 80%
compared to untreated cells (Fig. 3A). On the other hand,
treatment of VV-infected RAG cells with AZA did not
affect virus DNA accumulation. Figure 3B shows that the
yield and kinetics of viral DNA synthesis were similar in
the absence and presence of AZA throughout infection in
RAG cells. Therefore, although AZA interfered with virus
replication in both cell lines with similar effectiveness,
distinct steps of VV cycle were targeted by the drug
treatment.
VV protein synthesis in AZA-treated cells
Stages of VV replicative cycle can be conveniently
monitored by the pattern of protein synthesis on SDS–
polyacrylamide gels (Moss and Katz, 1969). To evaluate
the effect of AZA on VV protein expression, BSC-40 and
RAG cells were infected and treated with AZA, as before.
Viral proteins synthesized in the absence or presence of
AZA were analyzed by metabolic incorporation of
[35S]methionine at various times postinfection. After
pulse labeling, cell lysates were prepared and examined
by SDS–PAGE as described under Materials and Meth-
ods. The typical temporal pattern of VV gene expression
could be clearly observed in BSC-40 monolayers (Fig.
4A), whereas in RAG cells, this was less evident due to
the poor shutoff of host protein synthesis up to 12 h
FIG. 3. Viral DNA replication in infected cells treated with AZA.
BSC-40 (A) and RAG (B) cells were infected with VV at a multiplicity of
10 and treated with 25 g/ml AZA. At indicated times postinfection, cell
extracts were prepared and applied on nylon membranes, and hybrid-
ization was performed as described under Materials and Methods.
Autoradiograms were scanned and densitometry analysis was per-
formed using the image processing and analysis program Scion Image.
The numbers (arbitrary units) express the average value of three
different measurements.
FIG. 2. One-step infection in the presence of AZA. BSC-40 (A) and
RAG (B) cells were infected with VV at a multiplicity of 10 and treated
with 25 g/ml AZA. At indicated times postinfection, monolayers were
harvested for virus titration by plaque assay as described under Ma-
terials and Methods.
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postinfection (Fig. 4B). Therefore, early proteins were
detected in untreated VV-infected BSC-40 cells at 2 h
postinfection, and viral late polypeptides could be ob-
served at 8 h postinfection in juxtaposition to the shutoff
of host protein synthesis (Fig. 4A). In untreated RAG
cells, only viral late proteins were evident at 9 h postin-
fection (Fig. 4B). As expected based on the results of
monitoring DNA accumulation, the exposure of VV-in-
fected BSC-40 cells to AZA severely inhibited the syn-
thesis of viral late proteins compared to control cells (Fig.
4A). At 24 h postinfection, synthesis of late proteins was
not detected in the presence of AZA, and cellular trans-
lation was also completely impaired. The shutoff of host
protein synthesis was not due to a cytotoxic effect of the
drug, since the incubation of mock-infected monolayers
with AZA for 24 h did not alter the translation pattern (Fig.
4A). On the other hand, the treatment of VV-infected RAG
cells with AZA had no apparent effect on the expression
pattern of virus proteins; the timing of viral late protein
synthesis was virtually identical to that observed in con-
trol cells (Fig. 4B).
To further analyze the expression profiles of virus early
and late polypeptides, we then attempted to detect spe-
cific viral proteins that accumulated throughout infection.
For that, BSC-40 and RAG cells infected with VV were
incubated in the absence or presence of AZA, and at
different time points cell extracts were prepared for
SDS–PAGE. After transfer to a nitrocellulose membrane,
an immunoblotting was performed using polyclonal an-
tibodies raised against the early F11L gene product and
against total virion proteins. Figure 4C reveals that the
F11 protein accumulated continuously during the first 6 h
of infection in untreated BSC-40 and RAG cells. Incuba-
tion with AZA did not alter the F11 expression pattern in
both cell lines, suggesting that the prereplicative stage of
VV cycle was not affected during the AZA treatment. The
FIG. 4. Effect of AZA on protein expression in VV-infected cells. BSC-40 and RAG cells were infected with VV at a multiplicity of 10 and treated with
25 g/ml AZA. (A, B) At indicated times postinfection, BSC-40 (A) and RAG (B) monolayers were pulse-labeled with [35S]methionine for 30 min. The
cell lysates were prepared and analyzed by 12% SDS–PAGE, as described under Materials and Methods. Autoradiograms of the gels are shown. The
position and size (kDa) of prestained molecular weight markers are shown: (F) indicates the position of early viral proteins; () indicates late viral
proteins; (H) indicates a major host protein. (C, D) Viral early and late protein accumulation. At indicated times postinfection the monolayers were
harvested and analyzed by 10% SDS–PAGE, transferred to nitrocellulose membranes, and processed for immunoblotting using polyclonal anti-F11
antiserum (C) or antiserum raised against total proteins of highly purified VV-WR virions (D), as described under Materials and Methods. In (C) only
the relevant portion of the gel is shown. M refers to mock-infected cells; I refers to infected cells.
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accumulation of late proteins was detected by antibodies
raised against VV structural proteins. Control infections
in both cell lines showed similar profiles, although the
polypeptides were distinguished earlier in RAG extracts
(Fig. 4D). Consistent with the inhibition of viral DNA
replication, late protein levels were drastically reduced in
BSC-40 cells treated with AZA. In contrast, exposure of
VV-infected RAG cells to AZA exhibited a lesser effect on
the accumulation of late polypeptides compared to non-
treated cells, strengthening the observations made with
the metabolic-labeling assay. The data presented so far
indicate that viral DNA replication in BSC-40 cells is the
primary target of AZA treatment. On the other hand,
incubation of infected RAG monolayers with AZA appar-
ently does not affect viral gene expression, indicating
that AZA antiviral activity in RAG cells targets another
step of VV life cycle.
VV genome resolution in RAG cells treated with AZA
During the process of VV DNA replication, intermedi-
ate structures are formed, consisting of concatemeric
molecules that are resolved into monomers with hairpin
termini. The recently discovered late protein resolvase is
the enzyme responsible for the production of the mono-
meric genomes that are encapsidated during virus as-
sembly (Garcia and Moss, 2001). To investigate whether
AZA affects the resolution of VV genome in RAG cells,
total DNA was isolated from VV-infected cells, cleaved
with BstE II, and analyzed by Southern blot hybridization
to radiolabeled probes that identify VV DNA termini. The
restriction of resolved VV DNA with BstE II produces
1.3-kb terminal fragments, whereas a 2.6-kb fragment
indicates the presence of unresolved concatemer junc-
tions (Merchlinsky et al., 1988). Figure 5 shows the result
of a Southern blot hybridization analysis obtained after
BstE II digestion of DNA isolated from infected RAG
monolayers. In untreated virus-infected cells (Fig. 5,
lanes 1 to 3), nearly all the telomeric sequences were
resolved into the 1.3-kb form at the indicated times. This
result demonstrates the efficiency of VV concatemer res-
olution in RAG cells as described in other host cells
(DeMasi and Traktman, 2000; Hassett et al., 1997;
Sekiguchi and Shuman, 1997). In infected RAG cells
exposed to AZA, although the amount of accumulated
DNA appeared diminished at 6 h, at later times no
significant difference was observed compared to un-
treated cells. Furthermore, unresolved concatemers
were scarcely observed and the terminal sequences
were almost exclusively detected as the 1.3-kb mature
form, similar to untreated cells (Fig. 5, lanes 4 to 6). As
control, infected RAG-cells were treated with 45 M IBT
that inhibits VV late gene expression (Fig. 5, lanes 7 and
8). As described by others, a reduction of DNA and a
significant increase in the 2.6-kb unresolved concatem-
ers were observed (DeMasi and Traktman, 2000). Our
results show that AZA has no effect on VV genome
resolution.
Proteolytic processing of core proteins in VV-infected
RAG cells treated with AZA
As part of the maturation process, several VV core
proteins, including 4a and 4b, are produced by proteo-
lytic cleavage of immature precursors, e.g., p4a and p4b
(Vanslyke and Hruby, 1990). The inhibition of the proteo-
lytic processing is observed in cells treated with rifam-
picin, which also leads to an obstruction in the course of
virus morphogenesis (Sodeik et al., 1994). Therefore,
unsuccessful cleavage of the immature precursors is
often taken as a good indication of a deficient morpho-
genetic process. To evaluate the effect of AZA in the
proteolytic cleavage of the major core protein precur-
sors, p4a and p4b, a pulse-chase experiment was per-
formed in which VV-infected RAG cells were incubated
with [35S]methionine at 15 h postinfection for 1 h (pulse).
The radioactive medium was then removed and replaced
with fresh medium supplemented with a 100-fold excess
of cold methionine for the indicated times (chase). Anal-
ysis of the autoradiogram showed in Fig. 6 reveals that in
untreated RAG cells, p4a and p4b were efficiently pro-
cessed into the mature products 4a and 4b. Incubation of
VV-infected RAG cells with AZA did not affect the cleav-
age kinetics, and the ratio p4a/4a and p4b/4b during
chase were virtually similar to control cells.
Electron microscopy analysis of VV-infected RAG cells
Maturation of vaccinia virions is characterized by dis-
tinct steps that can be observed by electron microscopy.
FIG. 5. Effect of AZA on viral genome resolution. RAG cells were
infected with VV at a multiplicity of 10 and treated with 25 g/ml AZA.
At indicated times postinfection cells were harvested and total DNA
was isolated and digested with BstE II. A Southern blot was performed
and hybridized with a [32P]-telomeric region probe of VV DNA as
described under Materials and Methods. As control, VV-infected cells
were treated with 45 M IBT for 24 h and processed as above.
Autoradiograms of the blots are shown. Arrows indicate the 1.3-kb
mature telomeric fragment; arrowhead indicates the 2.6-kb nonre-
solved concatemeric fragment.
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Under normal assay conditions, assembly of virus parti-
cle is asynchronous and at late times all stages of
morphogenesis can be identified (Moss, 2001). In RAG
cells infected with VV for 24 h clusters of mature virions
and immature particles (IVs) were observed throughout
the cell cytoplasm at low magnification (Fig. 7A). In con-
trast, in VV-infected RAG cells treated with AZA the
amount of brick-shaped particles seemed to be reduced
with no apparent effect on the early stages of morpho-
genesis (Fig. 7B). Immature particles with internal elec-
tron-dense nucleoid structure (IVns) or without it were
evident in untreated infected cells (Fig. 7A), as well as
mature brick-shaped virions, as expected to occur as a
result of a productive infection (Fig. 7C). In AZA-treated
cells, immature particles were present from crescent
formation to IVs, IVns, and dense spherical particles (Fig.
7B). However, one can also note that most of the brick-
shaped virions produced in the presence of AZA bore a
resemblance to mature particles but showed a poor
definition on their overall structure, as if a step on virus
maturation from spherical IV to IMV was compromised
(Figs. 7D and 7E). A number of distinct EM preparations
of untreated and AZA-treated RAG cells infected with VV
were analyzed several times and the results were always
consistent with the picture where control viruses showed
a very characteristic and defined morphology but drug-
treated virions presented a blurred aspect in their struc-
ture. The amount of different forms of VV was quantitated
in different random fields of EM sections. As shown in
Table 2, in AZA-treated cells there was an increase in the
number of all immature forms and a decrease in the
amount of the mature particles when compared to un-
treated cells.
An interesting feature was the presence of mature
virus positioned side-by-side underneath the plasma
membrane, producing an appearance of a “string of
pearls” in many cross-sections of untreated RAG cells
(Fig. 8A and inset). However, in AZA-treated cells we
observed a general reduction of IMVs positioned
side-by-side at plasma membrane (Fig. 8B). It is also
of interest to note the presence of dense spherical
particles positioned underneath the cell membrane as
well as particles with a fuzzy structural aspect (Fig. 8B,
inset).
Comparative analysis of virions isolated from infected
cells
To further characterize the VV particles formed during
AZA treatment, RAG cells were infected with VV in the
presence or absence of AZA. At 24 h postinfection, the
monolayers were harvested and the intracellular virions
were purified through a sucrose-gradient centrifugation,
as described under Materials and Methods. Two major
bands were visualized in both gradients (data not
shown), collected separately, and analyzed for infectivity,
protein, and DNA contents. The analysis of infectivity and
particle number showed that AZA-treated cells produced
nearly 30% less particles than untreated cells and these
viruses were approximately 95% less infectious (Table 3).
In this condition, the ratio between infectious particles
and total particles was reduced 14- to 12-fold. The pro-
tein pattern from purified virions was also analyzed by
SDS–PAGE, as shown in Fig. 9A. Overall, the protein
profiles of the viruses collected from the two bands of the
same gradient appeared rather similar. On the other
hand, several differences were observed when we com-
pared virions isolated from untreated and AZA-treated
RAG cells. The arrows in Fig. 9A point out proteins
detected exclusively or more intensely in virus recovered
from untreated cells, while arrowheads indicate proteins
present only or more represented in virus isolated from
AZA-treated monolayers. Although we did not detect any
alteration in the processing event of p4a and p4b (Fig. 6),
the total amount of the major core proteins 4a and 4b
associated with particles purified from AZA-treated cells
appeared to be specifically reduced compared to the
amount of other proteins. Interesting dissimilarities were
also observed in low molecular weight polypeptides.
Three major bands appeared in the lower part of the gel
in virus isolated from AZA-treated cells that were appar-
ently absent in control virus.
The DNA content of purified virions collected from
both bands was analyzed by slot-blot as described under
Materials and Methods. As shown in Fig. 9B, the amount
of DNA present in virions isolated from AZA-treated cells
was reduced in both bands. Quantitation by densitomet-
FIG. 6. Proteolytic processing of p4a and p4b in AZA-treated cells.
RAG cells were infected with VV at a multiplicity of 10 and treated with
25 g/ml AZA. At 15 h postinfection cells were metabolic-labeled with
[35S]methionine for 1 h and either lysed immediately (lane 0) or chased
for the indicated times as described under Materials and Methods.
Radiolabeled samples were analyzed by 10% SDS–PAGE. An autora-
diogram of the gel is shown. The position and size (kDa) of prestained
molecular weight markers are shown. M refers to mock-infected cells.
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ric analysis indicated that the total DNA associated with
purified virions from AZA-treated cells was reduced to
56.3  0.1% (band 1) and 52.8  0.06% (band 2) of the
viral DNA present in control virions.
DISCUSSION
Antiviral agents can be differentiated in two groups:
one that acts in virus-encoded macromolecular synthe-
FIG. 7. Azathioprine inhibits the maturation of progeny virions. RAG cells were infected with VV at a multiplicity of 10 and untreated (A, C) or treated
with 25 g/ml AZA (B, D, E). At 24 h postinfection, the monolayers were fixed and processed for transmission electron microscopy as described under
Materials and Methods. Representative fields were photographed. Mature virus (IMV), immature particles (IV), and DNA factories (F) are visualized
in several areas of the cytoplasm. N, nucleus. Virions with atypical formation are pointed with arrowheads.
TABLE 2
Quantitation of Vaccinia Virus Particles Resolved by Electron Microscopy during AZA Treatment
Treatment
Number of particles (%)
IV Nucleoide Dense Mature Total
Control 211 (20.4%) 72 (6.9%) 125 (12.1%) 627 (60.6%) 1035 (100%)
AZA 376 (36.6%) 102 (9.9%) 199 (19.4%) 349 (34.1%) 1026 (100%)
Note. RAG monolayers were infected with VV at an m.o.i. of 10 in the absence or presence of 25 g/ml AZA. Random fields from control and
AZA-treated cells were analyzed, and the particles counted. During the counting procedure no distinction was made between IMV and the particles
presenting abnormal definition of the internal structure.
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sis, and the other that affects the cellular processes
required for virus reproduction (De Clercq, 1993). The
first group of agents has the advantage to specifically
stop viral replication, but in contrast can select a popu-
lation of resistant mutants. On the other hand, affecting
cellular metabolism the drug can induce cytotoxicity in
growing cells, but could also be relatively noncytotoxic in
nondividing cells. There is also the possibility of a drug
acting differently depending on the metabolism of the
cell. The results presented in this study show that the
inhibition of vaccinia virus replication by AZA depends on
the host cell line. After its uptake by the cell, AZA is
metabolized and produces two major metabolites: 6-mer-
captopurine (6-MP) and 1-methyl-4-nitro-5-imidazolyl. In
cell lines that have the salvage pathway of purine nucle-
otide biosynthesis, the thiopurine subproduct is metab-
olized to thiopurine nucleotides and incorporated into
DNA, impairing de novo synthesis (Aarbakke et al., 1997).
Thus, in BSC-40 cells the inhibition of viral replication
caused by AZA could be correlated to virus DNA synthe-
sis, since this step was repressed nearly 80%. Further-
more, late events requiring DNA replication did not oc-
cur. On the other hand, in RAG cells, an HGPRT-deficient
cell line, AZA caused no significant inhibition in virus
DNA synthesis, gene expression, DNA concatemer res-
olution, or even protein proteolytic processing of p4a and
p4b. In this situation, the inhibition of virus replication
was linked to altered virus morphogenesis since IVs
were visualized but there was a considerable reduction
in the amount of IMVs. At low magnification, nearly all the
IMVs resembled standard mature virions, but a deeper
analysis revealed that these IMVs exhibited reduced
definition in the viral envelope and core structure, sug-
gesting that one or more late steps in morphogenesis
have been affected by AZA treatment. These observa-
tions were substantiated with the analysis of virions
purified from AZA-treated RAG cells. In this condition, the
PFU:particles ratio was lower when compared to virions
purified from untreated cells. Furthermore, the protein
content of the purified virions showed significant differ-
ences when analyzed on SDS–PAGE, and the amount of
DNA encapsidated in particles from AZA-treated cells
was reduced approximately 50%. The absence of some
of the major dominant peptides in virus isolated from
AZA-treated cells could be due to protein modification
that occurs during virus assembly. This in turn could
contribute to the failure in the genome encapsidation,
although we do not exclude otherwise. Taking together,
the poor infectivity of the virions isolated from AZA-
treated cells does not appear to result from a single
event but from a sum of anomalous processes during
morphogenesis that leads to abnormal virus formation.
Vaccinia virus morphogenesis is a complex process
wherein several synthesized viral elements are associ-
ated with membranes of cellular origin and orderly in-
corporated to form a new particle. Assembly of the newly
formed virions has been the subject of several studies
but the process is still not well known. The earliest
visible stage of VV formation is the presence of mem-
branes with a crescent shape, derived from the endo-
plasmic reticulum, near electron-dense viral factories.
The protein E8R, a VV early gene product, was identified
as being involved in the early wrapping event of the DNA
by the ER (Tolonen et al., 2001).
FIG. 8. Vaccinia virions positioned underneath the membrane resem-
ble a “string of pearls.” RAG cells were infected with VV at a multiplicity
of 10 and untreated (A) or treated with 25 g/ml AZA (B). At 24 h
postinfection, the monolayers were fixed and processed for transmis-
sion electron microscopy as described under Materials and Methods.
Representative fields were photographed. Mature virus positioned
side-by-side underneath the plasma membrane, producing an appear-
ance of a string of pearls are pointed with arrowheads. Increased
magnification of particles underneath the membrane is visualized in the
insets.
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Several VV gene products such as F10, H5, A17, A14,
D13, A30, and A10 have been implicated in viral morpho-
genesis from crescent formation to immature virions.
Mutation in one these genes abrogates the formation of
IVs in different steps. In the absence of F10, H5, or A17
proteins viral morphogenesis is interrupted before cres-
cent formation (DeMasi and Traktman, 2000; Rodriguez
et al., 1995; Traktman et al., 1995; Wang and Shuman,
1995; Wolffe et al., 1996). However, when A10, A14, A30,
or D13 proteins are not expressed, crescents are pro-
duced but no IVs are observed (Heljasvaara et al., 2001;
Rodriguez et al., 1998; Szajner et al., 2001; Traktman et
al., 2000; Zhang and Moss, 1992). Since in AZA-treated
VV-infected RAG cells we were able to identify cres-
cent structures and IVs, we believe that these early steps
in morphogenesis were not affected by the drug treat-
ment.
A number of viral proteins are implicated on the next
step of morphogenesis. In this phase proteins A32, A9,
F18, G4, H3, E10, A3, I1, I7, L1, A5, A22, A8, and D6 are
claimed to be involved in viral morphogenetic process
from IVs to IMVs. Immature virus and some abnormal
particles are observed when A32, A9, F18, G4, H3, or E10
synthesis is repressed but no IMVs are detected (Cas-
setti et al., 1998; Lin et al., 2000; Senkevich et al., 2000;
White et al., 2000; Yeh et al., 2000; Zhang and Moss,
1991). Although IVs are present in the cell cytoplasm,
most of the time the spherical particles are depleted of
nucleoid formation in their internal structure. However, in
the absence of I1, I7, L1, A5, A22, A8, or D6 synthesis,
immature virions with nucleoid (IVns) are observed but
IMVs are not formed (Ericsson et al., 1995; Garcia and
Moss, 2001; Hu et al., 1996, 1998; Kane and Shuman,
1993; Klemperer et al., 1997; Ravanello and Hruby, 1994;
Williams et al., 1999). In these studies it is suggested that
the blockage occurs in a step further on in morphogen-
esis since nucleoids appear in most spherical particles.
The impairment of I8 and L4 expression promotes the
appearance of normal IMVs but they are noninfectious
(Fathi and Condit, 1991; Wilcock and Smith, 1994). De-
spite their normal appearance, L4-mutant IMVs are over
100-fold less infectious than wild-type particles and the
core transcription rate is drastically reduced (Wilcock
and Smith, 1996). Likewise, our data suggest that AZA
may affect this stage of VV assembly in RAG cells. In
addition to a reduction in the amount of IMVs, we also
detect IMV-like particles with poor structural definition.
Dense IVs are also observed adjacent to the plasma
membrane, unlike untreated cells. Finally, viruses puri-
fied from AZA-treated cells were 20 times less infectious
than the control virus. These data, however, do not allow
TABLE 3
Purification of Intracellular Virions from Untreated and AZA-Treated RAG Cells
Virus fraction Particles/mL  1011 % Control PFU/mL  1010 % Control Ratio PFU/particles Total reduction
C1 2.57 100 1.19 100 1:22 —
A1 1.81 70 0.057 4.8 1:317 14.4
C2 2.04 100 0.39 100 1:51 —
A2 1.5 74 0.024 6.2 1:625 12.2
Note. RAG monolayers were infected with VV at an m.o.i. of 10 in the absence (C) or presence (A) of 25 g/ml AZA. After 24 h of infection the cells
were harvested, and the cytoplasmic extracts were collected for virus purification by sucrose-gradient sedimentation, as described under Materials
and Methods. Two visible bands were collected in each gradient tube and denoted as 1 and 2. Virus yield was determined by plaque assay and
particle number was established by OD260nm reading.
FIG. 9. Protein profile and DNA content of purified virions. RAG cells
were infected with VV at a multiplicity of 10 and untreated (lanes C) or
treated with 25 g/ml AZA (lanes A). At 24 h postinfection, the mono-
layers were harvested and the viruses present in the cytoplasmic
extracts were purified by sucrose-gradient sedimentation, as described
under Materials and Methods. Two bands were visualized in each
gradient tube (lanes 1 and 2) and collected separately. (A) 1  1010
particles were analyzed by SDS–PAGE and Coomassie-blue staining.
(B) 1  108 particles were applied on the membrane, and the DNA
content was determined by hybridization to viral DNA probe.
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us to infer how AZA inhibits VV morphogenesis, since
several genes are involved in the success of this stage of
virion assembly. The isolation of AZA-resistant VV mu-
tants by classical genetic strategies will be necessary to
unravel the drug target in infected RAG cells. We are
currently further examining virions isolated from AZA-
treated RAG cells.
Vaccinia virus replication can also be inhibited by
several drugs at different stages of the virus replicative
cycle. It is interesting to note that the target of some
drugs in vitro may not necessarily correlate with their
mechanism of action in vivo. Novobiocin, a bacterial DNA
gyrase inhibitor, also inhibits VV type I topoisomerase
and core transcription in vitro (Foglesong and Bauer,
1984; Sekiguchi et al., 1996). Nevertheless, treatment of
VV-infected cells with novobiocin inhibits virus formation
at late stages of replication (Sekiguchi and Shuman,
1997). In this condition, all classes of viral proteins are
synthesized but morphogenesis is blocked at an early
stage. In addition, novobiocin inhibits the proteolytic pro-
cessing of virion major structural proteins p4a and p4b.
Rifampicin, a bacterial RNA synthesis inhibitor, also
leads to a blockade of the proteolytic processing of p4a
and p4b proteins and induces the appearance of large
cytoplasmic structures named rifampicin bodies, prior to
IVs formation (Sodeik et al., 1994; Zhang and Moss,
1992). Here we show that AZA, an immunosuppressant
that blocks the salvage pathway of purine nucleotide
biosynthesis, inhibited VV replication in RAG cells at the
morphogenesis stage of the virus cycle. Late stages of
virion assembly appeared to be affected, probably during
formation of full mature IMVs. Most importantly, no ef-
fect on virus DNA metabolism was observed. As well,
the immunosuppressant leflunomide inhibits HSV and
HCMV replication in a comparable manner. This drug
exhibits two known mechanisms of action: inhibition
of protein tyrosine kinase activity and inhibition of dihy-
droorotate dehydrogenase, a key enzyme in the biosyn-
thesis of pyrimidine nucleotide triphosphates. Never-
theless, leflunomide inhibits virus replication at the morpho-
genesis step, interfering with nucleocapsid tegumentation,
with no effect on the nucleic acid metabolism (Knight et
al., 2001).
Clinical interest in antipoxvirus drugs has been re-
cently stimulated by the threat of smallpox reemergence.
Furthermore, treatment of other human poxvirus agents,
such as molluscum contagiosum, monkeypox, and Can-
tagalo virus, might also be considered in the future
(Damaso et al., 2000; Esposito and Fenner, 2001). In
immunodeficient individuals, such as AIDS patients, in-
fection with poxviruses produces lesions that could be-
come more extensively spread, leading to a severe clin-
ical manifestation (Redfield et al., 1987). Therefore all
drugs with a potential antipoxvirus activity should be
considered for use in the treatment of such infections.
MATERIALS AND METHODS
Cells and virus
BSC-40 (African green monkey kidney) and RAG
(mouse renal adenocarcinoma) cells were maintained in
monolayer cultures at 37°C in Dulbecco’s modified Ea-
gle’s medium (Gibco-BRL Laboratories) supplemented
with 8% calf serum, 2% heat-inactivated fetal bovine se-
rum, 500 U/ml penicillin, 100 g/ml streptomycin, 50
g/ml gentamicin sulfate, and 2.5 g/ml fungizon. RAG
cultures were also supplemented with 1 mM sodium
pyruvate and 0.1 mM nonessential amino acids. RAG
cells were generously provided by H. Seuanez (Instituto
do Cancer, RJ, Brazil).
Vaccinia virus strain WR was available in the labora-
tory’s collection and propagated in BSC-40 cells as de-
scribed elsewhere (Damaso and Moussatche´, 1992a).
Azathioprine
Azathioprine was a generous gift from Microbiolo´gica
Ltda, RJ, Brazil. The drug was dissolved in 100% DMSO
and stored at 20°C as 1000 stock solution.
Vaccinia virus infection and virus yield analysis
Confluent BSC-40 and RAG cells, grown in 35-mm
plates, were infected with VV at an m.o.i. of 10. After a
30-min adsorption period, the inoculum was removed,
and the cells were incubated at 37°C with fresh medium
containing 0.1% DMSO (control cells), or a specified con-
centration of AZA, as indicated in the text. The plates
were then kept at 37°C for 24 h when the cells were
harvested for plaque assay. Monolayers from each plate
were collected in 500 l of cold water and submitted to
two cycles of freezing and thawing. Virus preparations
were diluted in DMEM and plaque assay was carried out
in monolayers of BSC-40 cells as described (Damaso
and Moussatche´, 1992a).
For one-step growth experiments, BSC-40 and RAG
cells were infected with VV at an m.o.i. of 10 and treated
with 25 g/ml AZA or 0.1% DMSO (control) at zero time.
At indicated times postinfection, the cells were har-
vested as described above for virus titration in BSC-40
monolayers (Damaso and Moussatche´, 1992b). All mea-
surements of virus production are expressed as an av-
erage of duplicate experiments.
Analyses of VV DNA slot-blot hybridization
Confluent 35-mm dishes of BSC-40 and RAG cells
were infected with VV as described. At different times
postinfection cells were harvested and extracts were
prepared as described previously (Damaso and Keller,
1994). Samples (40 l) of each extract were applied in
triplicate to a Hybond-N membrane (Amersham Pharma-
cia) using a Slot Blot Minifold II apparatus (Schleicher &
Schuell, Inc.). After filtration, the DNA was denatured in
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situ as described (Damaso and Keller, 1994). Nick-trans-
lated probe representing the 16-kb HindIII D fragment of
VV genome was used for hybridization carried out for
18 h at 44°C in formamide-containing solution. The blots
were washed three times at 65°C in 0.1 SSC, 1% SDS,
as described elsewhere (Damaso and Moussatche´,
1998), and exposed to X-ray films. For quantitation, the
autoradiograms were scanned and densitometry analy-
sis was performed using the image processing and anal-
ysis program Scion Image (Beta Release 4; Scion Cor-
poration).
For the analysis of the DNA content present in the
purified virions, 1  108 particles were applied in tripli-
cate onto the membrane and processed as described
above.
Protein synthesis analysis
[35S]methionine incorporation. Confluent 35-mm dishes
of BSC-40 and RAG cells were infected with VV as de-
scribed above. At indicated times of infection the cells
were pulse-labeled for 30 min at 37°C with 50 Ci/ml
[35S]methionine (Amersham Pharmacia Redivue Pro-mix)
in methionine-free MEM (Gibco-BRL) containing 25
g/ml AZA or 0.1% DMSO. Cells were then harvested in
SDS–sample buffer and samples were subjected to elec-
trophoresis in SDS–PAGE as described previously
(Damaso and Moussatche´, 1992a). The gels were dried
and exposed to X-ray films.
Detection of virus proteins by immunoblot. BSC-40 and
RAG monolayers were infected and treated with AZA as
described above. At indicated times postinfection, the
cells were harvested in SDS–sample buffer and sub-
jected to electrophoresis in SDS–PAGE, followed by
transfer to nitrocellulose membranes as described be-
fore (Damaso et al., 2000). The blots were processed for
immunodetection as described. Rabbit anti-F11L anti-
body (Alpha Diagnostic, Inc.) was prepared from purified
F11L (N. Moussatche´ and R. C. Condit, unpublished
data). Rabbit anti-VV serum was produced against total
proteins of highly purified VV (strain WR), as described
(Damaso and Moussatche´, 1998). Primary antibodies
were diluted 1:900 (anti-F11; 18 h) or 1:2000 (anti-VV; 1 h).
Polypeptides were detected by incubation with the ECL
Western blotting detection reagents (Amersham/Phar-
macia), as suggested by the manufacturer.
Telomere resolution assay
The telomere resolution assay was performed as de-
scribed (Sekiguchi and Shuman, 1997). Confluent RAG
monolayers (100-mm dishes) were infected with VV as
described above. At indicated times postinfection, the
cells were harvested by centrifugation and washed twice
in TEN (20 mM Tris–HCl, pH 8.0; 10 mM EDTA; 50 mM
NaCl). Pellets were resuspended in 50 l of TEN, fol-
lowed by addition of 250 l of TES (20 mM Tris–HCl, pH
8.0; 10 mM EDTA; 0.6% SDS), containing 200 g of Pro-
teinase K. The mixtures were incubated at 42°C for 4 h
and forced five times through a 25-G needle. DNA was
extracted twice with phenol-chloroform-isoamyl alcohol
and precipitated with two volumes of ethanol. After di-
gestion with 40 U of BstE II (New England BioLabs) for
20 h at 37°C, DNA was fractionated in 1% agarose gels
and transferred to Hybond-N membranes (Amersham
Pharmacia). The blots were hybridized as described
above, using nick-translated pBD6 (Merchlinsky et al.,
1988), kindly provided by M. Merchlinsky, U.S. Depart-
ment of Agriculture, Bethesda, MD.
Processing of virion proteins
For pulse-chase experiments, RAG monolayers
(35-mm dishes) were infected with VV as described
above. At 15 h postinfection, the medium was removed
and the cells were incubated with methionine-free MEM
(Gibco-BRL) containing 25 g/ml AZA and 100 Ci/ml
[35S]methionine (Amersham Pharmacia Redivue Pro-mix)
for 1 h at 37°C. The monolayers were then washed and
overlaid with fresh medium supplemented with a 100-fold
excess of unlabeled methionine for indicated times. The
cells were harvested in sample buffer and proteins re-
solved in 10% SDS–PAGE as described above.
Electron microscopy
For electron microscopy studies, RAG monolayers
(60-mm dishes) were infected with VV as described
above. At 24 h postinfection, the monolayers were
washed twice with PBS at room temperature and then
fixed when still adhered to culture dish in a solution
containing 2.5% glutaraldehyde in 0.1 M cacodylate
buffer, pH 7.2. The cells were scraped off the dish,
washed in 0.1 M cacodylate buffer, and postfixed for 60
min at 4°C in a solution containing 1% osmium tetroxide
in 0.1 M cacodylate buffer. Subsequently, the cells were
washed in buffer, dehydrated in acetone, and embedded
in Epon. Ultrathin sections were stained with uranyl ac-
etate and lead citrate and observed in a Zeiss CEM-902
electron microscope (Damaso et al., 2000).
Virus purification
Four confluent 150-mm dishes of RAG cells were in-
fected with VV at an m.o.i. of 10 and treated with 25 g/ml
AZA or 0.1% DMSO (control) at zero time as described
above. After 24 h of infection the monolayers were har-
vested in 10 mM Tris–HCl pH 7.5 and Dounce homoge-
nized. The extracts were clarified by low-speed centrifu-
gation and the virus present in the cytoplasmic fraction
was purified by centrifugation through a 36% sucrose
cushion and sedimentation in a 25–40% sucrose gradi-
ent, as described (Damaso and Moussatche´, 1992b;
Damaso et al., 2000). Equal volumes of the banded viri-
ons were aspirated, collected by centrifugation, and the
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virus resuspended in 500 l of 10 mM Tris–HCl, pH 7.5.
The number of particles was determined, assuming that
one A260 unit corresponds to 1.2  10
10 particles per ml.
All viruses were titrated in BSC-40 cells as described
above.
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